Two Sigma Investments LP Cuts Position in C4 Therapeutics, Inc. (NASDAQ:CCCC)

Two Sigma Investments LP decreased its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) by 31.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 563,837 shares of the company’s stock after selling 264,653 shares during the quarter. Two Sigma Investments LP owned about 0.80% of C4 Therapeutics worth $2,030,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Rhumbline Advisers raised its position in C4 Therapeutics by 4.6% in the fourth quarter. Rhumbline Advisers now owns 100,015 shares of the company’s stock worth $360,000 after acquiring an additional 4,366 shares in the last quarter. Sei Investments Co. purchased a new position in C4 Therapeutics in the fourth quarter worth $45,000. American Century Companies Inc. raised its position in C4 Therapeutics by 8.5% in the fourth quarter. American Century Companies Inc. now owns 132,832 shares of the company’s stock worth $478,000 after acquiring an additional 10,459 shares in the last quarter. Jane Street Group LLC raised its position in C4 Therapeutics by 49.4% in the fourth quarter. Jane Street Group LLC now owns 152,774 shares of the company’s stock worth $550,000 after acquiring an additional 50,523 shares in the last quarter. Finally, Balyasny Asset Management L.P. raised its position in C4 Therapeutics by 115.4% in the fourth quarter. Balyasny Asset Management L.P. now owns 42,533 shares of the company’s stock worth $153,000 after acquiring an additional 22,789 shares in the last quarter. Hedge funds and other institutional investors own 78.81% of the company’s stock.

Analysts Set New Price Targets

Separately, UBS Group raised C4 Therapeutics to a “hold” rating in a report on Friday, February 14th.

C4 Therapeutics Stock Performance

C4 Therapeutics stock opened at $1.24 on Monday. The firm has a market capitalization of $87.69 million, a price-to-earnings ratio of -0.73 and a beta of 3.10. C4 Therapeutics, Inc. has a fifty-two week low of $1.09 and a fifty-two week high of $7.66. The stock’s fifty day moving average is $1.44 and its two-hundred day moving average is $2.76.

C4 Therapeutics (NASDAQ:CCCC) last posted its earnings results on Wednesday, May 7th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.11. The company had revenue of $7.20 million for the quarter, compared to analyst estimates of $3.54 million. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. As a group, sell-side analysts forecast that C4 Therapeutics, Inc. will post -1.52 EPS for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.